A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00655707|
Recruitment Status : Completed
First Posted : April 10, 2008
Last Update Posted : June 8, 2015
This is a prospective dose escalation study of the administration of adult human stem cells in patients with end stage liver failure. Successive groups of two patients will receive ascending doses of autologous adult human stem cells starting at 1x10 cells. Following expansion in an approved GMP facility the cells will be infused into either the hepatic artery or portal vein of research participants.
The aim of this trial is to determine the maximum tolerated dose of autologous adult stem cells when infused into either the hepatic artery or the portal vein. The maximum dose that would be given would be 5x10 to the ten .
To assess improvement in liver function as measured by serological and biochemical analysis and determine whether there are any symptomatic improvements as reported by the patients.
|Condition or disease||Intervention/treatment||Phase|
|Liver Disease||Biological: Autologous Expanded CD34+ Haemopoietic cells||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Safety and Tolerability Dose Escalation Study Following the Autologous Infusion of Expanded Adult Haematopoietic Stem Cells to Patients With Liver Insufficiency|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||April 2009|
|Actual Study Completion Date :||April 2009|
Autologous CD34+ cells
Biological: Autologous Expanded CD34+ Haemopoietic cells
Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.
Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells
- To determine the maximum tolerated dose of autologous adult stem cells when infused into either the hepatic artery or the portal vein. [ Time Frame: 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00655707
|Imperial College Healthcare Trust|
|London, United Kingdom, W12 0HS|
|Principal Investigator:||Nagy Habib, ChM FRCS||Imperial College London|